Premium
The Alzheimer's disease peptide β‐amyloid promotes thrombin generation through activation of coagulation factor XII
Author(s) -
Zamolodchikov D.,
Renné T.,
Strickland S.
Publication year - 2016
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.13209
Subject(s) - coagulation , thrombin , amyloid (mycology) , factor xii , tissue factor , fibrin , alzheimer's disease , medicine , chemistry , neuroscience , immunology , disease , platelet , pathology , biology
Essentials How the Alzheimer's disease (AD) peptide β‐amyloid (Aβ) disrupts neuronal function in the disease is unclear. Factor (F) XII initiates blood clotting via FXI, and thrombosis has been implicated in AD. Aβ triggers FXII‐dependent FXI and thrombin activation, evidence of which is seen in AD plasma. Aβ‐triggered clotting could contribute to neuronal dysfunction in AD and be a novel therapeutic target.Summary Background β‐Amyloid (Aβ) is a key pathologic element in Alzheimer's disease ( AD ), but the mechanisms by which it disrupts neuronal function in vivo are not completely understood. AD is characterized by a prothrombotic state, which could contribute to neuronal dysfunction by affecting cerebral blood flow and inducing inflammation. The plasma protein factor XII triggers clot formation via the intrinsic coagulation cascade, and has been implicated in thrombosis. Objectives To investigate the potential for Aβ to contribute to a prothrombotic state. Methods and results We show that Aβ activates FXII , resulting in FXI activation and thrombin generation in human plasma, thereby establishing Aβ as a possible driver of prothrombotic states. We provide evidence for this process in AD by demonstrating decreased levels of FXI and its inhibitor C1 esterase inhibitor in AD patient plasma, suggesting chronic activation, inhibition and clearance of FXI in AD . Activation of the intrinsic coagulation pathway in AD is further supported by elevated fibrin levels in AD patient plasma. Conclusions The ability of Aβ to promote coagulation via the FXII ‐driven contact system identifies new mechanisms by which it could contribute to neuronal dysfunction and suggests potential new therapeutic targets in AD .